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Utility of repeat cytological assessment
of thyroid nodules initially classified
as benign: clinical insights from
multidisciplinary care in an Irish tertiary
referral centre
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Abstract
Background: Fine needle aspiration biopsy (FNAB) is the tool of choice for evaluating thyroid nodules with the
majority classified as benign following initial assessment. However, concern remains about false negative results and
some guidelines have recommended routine repeat aspirates. We aimed to assess the utility of routine repeat FNAB
for nodules classified as benign on initial biopsy and to examine the impact of establishing a multidisciplinary team
for the care of these patients.
Methods: We performed a retrospective review of 400 consecutive patients (413 nodules) who underwent FNAB of
a thyroid nodule at our hospital between July 2008 and July 2011. Data recorded included demographic, clinical,
histological and radiological variables.
Results: Three hundred and fifty seven patients (89 %) were female. Median follow-up was 5.5 years. Two hundred
and fifty eight (63 %) nodules were diagnosed as benign. The rate of routine repeat biopsy increased significantly
over the time course of the study (p for trend = 0.012). Nine Thy 2 nodules were classified differently on the basis of
routine repeat biopsy; one patient was classified as malignant on repeat biopsy and was diagnosed with papillary
thyroid carcinoma. Eight were classified as a follicular lesions on repeat biopsy—six diagnosed as benign following
lobectomy; two declined lobectomy and were followed radiologically with no nodule size increase.
Conclusions: The false negative rate of an initial benign cytology result, from a thyroid nodule aspirate, is low. In
the setting of an experienced multidisciplinary thyroid team, routine repeat aspiration is not justified.
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Background
Thyroid nodules are palpable in 5 % of the population in
iodine sufficient regions and in a much higher percent-
age in iodine deficient countries [1, 2]. However, neck
ultrasound (US) identifies nodules in almost 40 % of the
population [3]. The majority of nodules are benign with
malignancy diagnosed in approximately 5–12 % of ultra-
sound detected nodules [4, 5].
An increasing number of thyroid nodules are inciden-
tally detected by various modalities of imaging of the
neck and thorax and contribute to an increased work-
load for endocrinologists, pathologists and radiologists.
Several international societies have produced multidis-
ciplinary guidelines for the assessment and management
of thyroid nodules [6–9]. The overall objective of clini-
cians is to diagnose malignancy pre-operatively in pa-
tients with thyroid carcinoma and to limit unnecessary
surgery in the vast majority with benign nodules. Neck
ultrasound and fine-needle aspiration biopsy (FNAB) are
promoted as the tools of choice for diagnosis.
Nodules classified as “benign” on cytology, following
FNAB, account for the greatest proportion of cases seen
in routine clinical practice [10]. However, cytological as-
sessment of samples is somewhat subjective with several
factors influencing the diagnostic outcome including the
experience of the cytopathologist, as well as the ad-
equacy of the sample [11, 12]. The negative predictive
value of a “benign” cytology result is difficult to define
and concern exists over false negative (falsely reassuring)
results typically ranging from 1–11 %, potentially result-
ing in missed cancer diagnosis [13–18]. All guidelines
recommend clinical follow-up for this group of patients.
However, debate exists regarding the need for repeat
cytological aspiration for nodules initially classified as
benign [6].
Methods
The primary aim of the study was to evaluate the utility
of routine repeat FNAB for nodules initially classified as
benign. Secondary aims were to determine the distribu-
tion of cytological diagnostic categories among a large
cohort of unselected patients with thyroid nodules and
to examine the effect of a multidisciplinary team on the
assessment and care pathway of patients with thyroid
nodules.
We performed a retrospective review of 400 consecu-
tive patients (413 nodules) who underwent FNAB of a
thyroid nodule at our hospital between July 2008 and
July 2011. Thirteen patients had assessment of more
than one nodule.
Patients were identified from the Department of Path-
ology database (WINPATH). All FNA biopsy results
were reported according to the Royal College of Patholo-
gists Thy Classification System (Table 1) [19]. Nodules
were aspirated routinely if they were greater than 1.5 cm
in diameter with any solid component or if they were
less than 1.5 cm in diameter with suspicious clinical or
sonographic features. Data recorded include demo-
graphic, clinical, cytological and radiological variables.
Data were collected by retrospective chart review of
patients receiving routine clinical care and follow-up. All
patients gave informed consent for FNAB in the context
their standard clinical care. No further measures were
taken beyond those of routine clinical practice. Data col-
lection was undertaken via clinical audit by physicians
caring for the patients; formal review and approval by
the Research Ethics Committee was not required.
The first year of the study (July 2008–June 2009 inclu-
sive) preceded the establishment of a formal multidiscip-
linary team for the management of thyroid nodules.
During this period, thyroid aspirates were reported in a
descriptive fashion rather than being stratified according
to a cytological classification system. For all nodules
evaluated during this period, the original slides were
reviewed by a single cytopathologist and a Thy grade
was assigned. Prospective reporting of thyroid aspirates
according to the Thy classification system was imple-
mented after June 2009.
A multidisciplinary team (MDT) for the management
of thyroid nodules and thyroid cancer was established in
July 2009 including specialists from thyroidology, endo-
crine surgery, histocytopathology, radiology, chemical
pathology and radiation oncology. In addition to the
routine reporting of Thy grade on cytology samples, the
MDT developed an agreed protocol for the assessment
of thyroid nodules based on the guidelines of the British
Thyroid Association: 2007 Update (5).
The initial cytology category assigned to each nodule
informed the management and surveillance as follows:
 Thy 1 (insufficient sample)—cases were discussed
by the MDT and follow up involved repeat biopsy,
surgical resection or clinical/radiological follow-up
based on the risk profile and patient preference.
 Thy 2 (benign)—Routine repeat FNAB, after
6 months, was recommended to exclude a false
negative result.
 Thy 3 (atypia or follicular lesion)—A lobectomy was
offered for formal histological diagnosis
Table 1 Cytological classification following first FNAB [19]
Thy category Description No. of biopsies (%)
Thy 1 Inadequate/non-diagnostic 63 (15)
Thy 2 Benign 258 (63)
Thy 3 Follicular lesion 75 (18)
Thy 4 Suspicious for malignancy 8 (2)
Thy 5 Malignant 9 (2)
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 Thy 4 (suspicious for malignancy)—Thyroidectomy
was recommended due to the high risk of
malignancy.
 Thy 5 (malignant)—Thyroidectomy was
recommended due to the very high risk of
malignancy.
Eighty nine percent of aspirates were performed under
US guidance. The MDT met twice monthly during the
study period to discuss both routine and complex cases.
Statistics
Mean and standard error of the mean (SEM) were deter-
mined for normally distributed continuous data and me-
dian (standard deviation or range) was used for data not
normally distributed.
The study period was divided into quartiles. MDT per-
formance indicators were assessed in each quarter and
trend analysis was performed using Chi square test. Stat-
istical analysis was performed using GraphPad Prism 5
software (GraphPad Inc., La Jolla, CA, 2010).
Results
Three hundred and fifty seven patients (89 %) were fe-
male. Median age was 54 years (range 16–89). Median
nodule size (measured on ultrasound in 217 cases) was
25 mm in maximum transverse diameter. Only seven
nodules were less than 10 mm in size. Median follow-up
was 5.5 years (range 4.4–7.9).
Two hundred and thirty nine (58 %) nodules under-
went a single biopsy; 156 (38 %) had a second biopsy.
14(3 %) and 4(1 %) underwent a third and fourth biopsy
respectively. The distribution of initial Thy category is
outlined in Table 1.
Nodules with benign cytology (Thy2)
Overall, 258 nodules (63 %) were initially classified as
Thy 2 (benign). Management of patients with a nodule
initially classified as Thy 2 (benign) is outlined in Fig. 1.
Twenty three patients (9 %) elected, subsequently, to
have surgery rather than conservative follow-up (lobec-
tomy or thyroidectomy), principally due to local com-
pressive symptoms (subjective or objective) or for
cosmetic reasons—all were diagnosed as benign nodules.
Among the remainder of this patient group, 126/235
(54 %) underwent routine repeat biopsy. The rate of rou-
tine repeat biopsy increased significantly over the time
course of the study; p for trend = 0.012 (Fig. 2).
Nine Thy 2 nodules were classified differently follow-
ing routine repeat biopsy (Fig. 1, Table 2). One patient
was classified as Thy 5 (malignant) on repeat FNAB and
was diagnosed with a solitary 3 cm papillary thyroid car-
cinoma (PTC) following a thyroidectomy—the entire
nodule was malignant; the lesion had classical PTC
morphology in some areas and in others demonstrated a
Warthin-like tumour appearance. Two level VI cervical
lymph nodes contained metastatic PTC - (Stage 1,
pT2N1aM0). Eight were classified as Thy 3 after repeat
aspiration; six underwent thyroid lobectomy and were
diagnosed as benign; two declined lobectomy—they were
followed with surveillance ultrasound and the nodules
remained stable in size during 3 year follow up.
258 Thy 2 on intital 
FNAB
23 resected after first 
FNAB
All benign on histology
126 routine repeat 
FNAB
One Thy 5
Papillary Thyroid 
carcinoma on histology
Eight Thy 3
Six underwent 
diagnostic lobectomy -
all benign on histology
Two declined lobectomy 
- stable US appearances 
on follow -up
117 Thy 2 
109  followed 
clinically/radiologically
Fig. 1 Routine management of patients with a thyroid nodule initially classified as Thy 2(benign)
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The majority of patients with a nodule initially classified
as Thy 2, who did not have surgery or a repeat biopsy,
were followed for between 4–8 years without clinical or
sonographic evidence of significant nodule enlargement.
Therefore, the negative predictive value (NPV) of a Thy 2
biopsy was greater than 99 %; only one of 258 nodules,
initially classified as benign, was subsequently found to
harbor malignancy. If only biopsies which were repeated
or followed by surgical resection are considered (n = 149),
the NPV of an initial Thy 2 biopsy still exceeds 99 %.
Nodules with other cytological classifications
Use of ultrasound guidance was significantly higher
among sufficient/diagnostic (Thy2-Thy5) category aspi-
rates in comparison with non-diagnostic aspirates (94 %
versus 76 % of aspirates respectively). Therefore, lack of
ultrasound guidance was strongly associated with insuffi-
cient biopsy material (p value < 0.0001).
Sixty three nodules (15 %) were initially classified as Thy
1 (insufficient). Twenty seven (43 %), of the nodules initially
classified as Thy1, were predominantly or partially cystic in
nature. Nineteen percent (12/63) of those initially classified
as Thy 1 underwent surgical resection while 52 % (33/63)
were re-biopsied. In the former group (surgically resected
nodules), 4/12 patients were diagnosed with a malignant
lesion. Repeat biopsy of a nodule originally classified as Thy
1 yielded a diagnostic sample in 57 %. Among those
patients with two consecutive biopsies classified as Thy 1
(n = 12), four underwent surgery and 1 of the 4 had a
malignant lesion diagnosed −2.7 cm locally invasive papil-
lary thyroid carcinoma. The remaining patients, with either
one or two insufficient cytology samples (n = 28), were
followed clinically and/or radiologically and did not develop
any concerning features to warrant resection.
Seventy five (18 %) of nodules were assigned to the Thy 3
category (atypia, follicular lesion or follicular neoplasm).
The majority of Thy 3 nodules (55/75) were surgically ex-
cised; 29 % (16 nodules) were ultimately diagnosed as ma-
lignant. The rate of lobectomy for Thy 3 nodules increased
significantly over the course of the study—p for trend 0.026
(Fig. 3). The remaining 20 patients have been followed with
serial ultrasound—no nodule has increased significantly in
size or developed any new suspicious radiological features.
Eight (2 %) nodules were initially classified as Thy 4
(suspicious for malignancy)—all proceeded to surgical
resection. One patient was diagnosed with medullary
thyroid carcinoma. Among the remainder, one patient
Fig. 2 Trend (dotted line) for repeat FNA after initial aspirate classified
as Thy 2 (benign); p for trend = 0.012. Solid line represents the absolute
percentage of aspirates, initially classified as Thy 2, which were
repeated in each quarter of the study period
Table 2 Final cytological category of 126 nodules, initially
classified as Thy2 (benign) after routine repeat FNAB
Result of routine 2nd FNAB No. of nodules (%)
Thy 1 0 (0)
Thy 2 117 (92.8)
Thy 3 8 (6.4)
Thy 4 0 (0)
Thy 5 1 (0.8)
Fig. 3 Trend (dotted line) for lobectomy following Thy 3 aspirate;
p for trend 0.026. Solid line represents the absolute percentage of
nodules classified as Thy 3 which were surgically resected during
each quarter of the study period
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was diagnosed with stage IV papillary thyroid carcinoma
(PTC) while all others had stage I PTC. Thy 5 (malig-
nant) nodules accounted for 2 % of cases (9 nodules).
All had malignancy diagnosed following thyroidecto-
my—all patients had stage I differentiated thyroid
cancer.
Discussion
We describe the cytological findings and outcome in a
large, consecutive series of patients who underwent diag-
nostic evaluation of thyroid nodules. The gender distribu-
tion and nodule size in our cohort are comparable to other
large case series. However, length of follow up in our cohort
is considerably longer than many studies in this field.
In keeping with previous research, most nodules in
our cohort were classified as benign (Thy 2) after cyto-
logical assessment [10]. There is on-going debate, inter-
nationally, about the appropriate follow up of such
cases. Guidance varies between repeat clinical, ultra-
sound and/or cytological assessment [6–9]. During the
time course of this study, we adopted the contemporary
recommendations of The British Thyroid Association to
perform a routine repeat aspiration of lesions initially
classified as benign (Thy 2) to rule out a false negative
result [6].
Among the Thy 2 nodules in our cohort, 7 % had a
different classification on repeat biopsy. However,
amongst 126 patients who had a repeat FNAB, only one
patient (0.8 %) initially classified Thy 2 was ultimately
diagnosed with differentiated papillary carcinoma. Con-
sidering all nodules initially categorised as Thy 2 or only
those who underwent repeat biopsy or surgery, the nega-
tive predictive value (NPV) of an initial benign cytology
assessment exceeded 99 %. The majority of patients with
benign cytology findings do not proceed to thyroidec-
tomy and, given the indolent nature of many differenti-
ated thyroid malignancies, there are concerns that a
short follow up interval may lead to a verification bias
and consequent overestimate of the NPV. In our
study, only 23 (9 %) patients with initial benign cy-
tology underwent surgical resection; however the long
follow up (range 4–8 years) gives more credence to
our conclusions.
Advocates of routine repeat FNAB of benign thyroid
nodules on initial cytology voice concerns about false
negative results and missed diagnoses of thyroid cancer.
False negative rates, following a benign biopsy result,
have been reported to be as high as 11 % in some histor-
ical series [17]. This led some authors to conclude that
repeat aspiration is useful to reduce the rate of false
negative results [17, 20, 21]. However, much of this data
precede the widespread use of ultrasound-guided FNA
resulting in a better cytological yield. In addition, cy-
tology results were, previously, often not reported
according to a validated classification system. Further-
more, repeat biopsies were not undertaken on a routine
basis but, rather, were performed on the basis of clinical
suspicion in many cases, leading to a somewhat biased
study cohort.
Hamburger et al., in one of the few studies to per-
form routine repeat aspiration of benign thyroid nod-
ules (not guided by ultrasound), reported that 9 %
were assigned a different classification on repeat bi-
opsy; 3 % were diagnosed with malignancy following
thyroidectomy [13]. More recent research by Singh
Ospina et al. reported that 1.2 % of nodules were
classified as malignant when the FNAB was repeated
after an initial benign cytological assessment-334 nod-
ules, initially classified as benign, underwent repeat
aspiration over a 10 year period; however, the authors
do not report what proportion of initially benign
biopsies were repeated [14]. Higher false negative bi-
opsy rates-approximately 2.5 %—have been described
in other recent retrospective studies [15, 22]. How-
ever, re-biopsy was undertaken on a selective basis,
based on clinical or radiological concern during follow up,
as opposed to the routine policy favoured in our study.
Recent research has more accurately defined the natural
history of nodules initially classified as benign; in a study
of over 2000 such nodules, followed for over 8 years, there
were no deaths due to thyroid cancer; thyroidectomy was
undertaken in 24 % and the false negative rate was esti-
mated at 1.3 % [18].
Enhanced resolution of ultrasound scanners has im-
proved risk stratification of thyroid nodules. Several ultra-
sound features (e.g. irregular border, intranodular
vascularity, hypoechoic echotexture, microcalcifications)
have been shown to be more common in malignant thy-
roid lesions [23]. Ultrasound characteristics, combined
with clinical features and specific risk factors can be used
to risk stratify patients and inform the decision about the
need for repeat biopsy [24, 25]. This approach is now
advocated by many international experts and professional
societies, who have suggested that routine repeat biopsy of
nodules classified as Thy 2 (benign) may not be necessary
in all cases [7]. Alternatively, nodules could be risk
assessed according to the patient’s history as well as clin-
ical and ultrasound features. Low risk lesions may not
require biopsy. Furthermore, the size of the lesion is now
recognised as a less important independent determinant
of risk, unless the lesion has increased in size [26].
Multidisciplinary care is advocated for all patients with
thyroid nodules and cancer [7]. However, there is a pau-
city of clinical data evaluating this approach to the care
of this subgroup of patients [10]. Our local MDT was
established towards the beginning of the study period
and the temporal trends allow some assessment of its
impact on patient care.
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There was a high rate of Thy 1 (non-diagnostic/inad-
equate) aspirates in our series. Previous research has
shown the value of US guidance in attaining a diagnostic
sample [27]. Lack of US guidance in our study was
strongly associated a non-diagnostic aspirate. Our rate
of routine repeat biopsy increased significantly through-
out the duration of the study (Fig. 1). This temporal
trend supports the notion of increased integration of the
MDT over time with improved implementation of a
shared-care protocol.
Cytology has been shown to be inaccurate in distinqu-
ishing benign and malignant follicular lesions—ie Thy 3
lesions. International guidelines advise diagnostic lobec-
tomy in such cases with predominantly follicular fea-
tures (as opposed to those with only atypical cellular
features) [7]. Our rate of lobectomy for Thy 3 lesions in-
creased significantly throughout the study period—Fig. 2.
We believe this may due to the establishment of the
MDT which promoted a protocolisedapproach to care in
line with international guidelines. The malignancy rate
in Thy3 nodules in our study is somewhat higher than
other series. However, only 75 % of our Thy 3 nodules
were excised and this sample may be biased due to clin-
ical and/or radiological concern about patients sent for
surgery. Long-term clinical follow-up of non-operated
Thy 3 nodules has not raised any concern or led to a
recommendation for surgery.
Thy 4 category (suspicious for malignancy) only
accounted for 2 % of nodules. However, all cases were di-
agnosed with malignancy after thyroidectomy. This may
represent an over-reliance on this category as similar stud-
ies report malignancy rates between 60–80 % for this cyto-
logical category [10, 28, 29]. However, the number of Thy
5 (malignant) lesions is in keeping with international lit-
erature with no false positive cases. This emphasises the
positive predictive value of fine-needle aspiration in the
preoperative diagnosis of thyroid cancer.
This study supports and extends the findings of similar
studies in this field. Very few previous studies have ex-
amined the impact of a routine repeat FNAB in patients
with a thyroid nodule initially classified as benign, re-
gardless of the clinical or radiological features. Our data
support a very high accuracy of an initial, well-targeted
FNAB with only 7 % of nodules receiving a different
classification on re-biopsy and <1 % diagnosed with ma-
lignancy. The long follow up of our cohort adds further
weight to our findings.
This study is limited mainly by the retrospective de-
sign. There may be a selection bias in the patients that
had repeat biopsy, influenced by clinician and patient
opinion at the time of evaluation but this is unlikely to
have resulted in an underestimation of false negative re-
sults, as one would expect that if selection bias was a
factor, it would have resulted in more diagnoses of
thyroid carcinoma on repeat FNAB. In addition, greater
detail of the ultrasound characteristics of nodules would
have permitted analysis of these features for risk stratifi-
cation of nodules. Finally, the study reports routine prac-
tice in a tertiary referral centre and the results may be
challenging to reproduce in centres with a smaller case
load, less complex case mix and where a similar, broad-
based multidisciplinary team is not available.
Conclusion
We conclude that the risk of malignancy in thyroid nod-
ules initially classified as Thy 2 (benign), by an experi-
enced cytopathologist, is very low when the FNAB is
well-targeted and cases are managed by a MDT. Repeat
biopsy is not necessary in all patients but could be re-
served for selected cases with high risk clinical and/or
radiological features.
In addition, the establishment of a multidisciplinary
team, for the care of patients with thyroid nodules, is as-
sociated with improved implementation of international
guidelines.
Abbreviations
FNAB, fine needle aspiration biopsy; MDT, multidisciplinary team; US,
ultrasound; NPV, negative predictive value; SEM, standard error of mean; SD,
standard deviation
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